| Lennox-Gastaut Syndrome
Fintepla vs Epidiolex
Side-by-side clinical, coverage, and cost comparison for lennox-gastaut syndrome.Deep comparison between: Fintepla vs Epidiolex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEpidiolex has a higher rate of injection site reactions vs Fintepla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Epidiolex but not Fintepla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fintepla
Epidiolex
At A Glance
Oral
Twice daily
5-HT2 receptor agonist
Oral
Twice daily
Cannabinoid antiepileptic
Indications
- Infantile Severe Myoclonic Epilepsy
- Lennox-Gastaut syndrome
- Lennox-Gastaut syndrome
- Infantile Severe Myoclonic Epilepsy
- Tuberous Sclerosis
Dosing
Infantile Severe Myoclonic Epilepsy, Lennox-Gastaut syndrome Initial 0.1 mg/kg twice daily orally, titrated weekly; maintenance up to 0.35 mg/kg twice daily (max 26 mg/day); with concomitant stiripentol plus clobazam, maximum 0.2 mg/kg twice daily (max 17 mg/day).
Lennox-Gastaut syndrome, Infantile Severe Myoclonic Epilepsy Starting 2.5 mg/kg orally twice daily (5 mg/kg/day); increase after 1 week to maintenance 5 mg/kg twice daily (10 mg/kg/day); may increase up to maximum 10 mg/kg twice daily (20 mg/kg/day) in weekly increments based on response and tolerability.
Tuberous Sclerosis Starting 2.5 mg/kg orally twice daily (5 mg/kg/day); increase weekly by 2.5 mg/kg twice daily (5 mg/kg/day) as tolerated to recommended maintenance 12.5 mg/kg twice daily (25 mg/kg/day).
Contraindications
- Hypersensitivity to fenfluramine or any of the excipients in FINTEPLA
- Concomitant use, or within 14 days of administration, of monoamine oxidase inhibitors
- History of hypersensitivity to cannabidiol or any excipient in EPIDIOLEX
Adverse Reactions
Most common (>=10%) Decreased appetite, somnolence/sedation/lethargy, diarrhea, fatigue/malaise/asthenia, abnormal echocardiogram, ataxia/balance disorder/gait disturbance, blood pressure increased, drooling/salivary hypersecretion, pyrexia, upper respiratory tract infection, vomiting, weight decreased
Serious Valvular heart disease, pulmonary arterial hypertension, decreased appetite and decreased weight, somnolence/sedation/lethargy, suicidal behavior and ideation, serotonin syndrome, increase in blood pressure, glaucoma, status epilepticus
Postmarketing Aggression
Most common (>=10%) Somnolence, decreased appetite, diarrhea, transaminase elevations, fatigue, malaise, asthenia, rash, insomnia, pyrexia, vomiting
Serious Hepatic injury, somnolence and sedation, suicidal behavior and ideation, hypersensitivity reactions
Pharmacology
Fenfluramine and its metabolite norfenfluramine exhibit agonist activity at serotonin 5-HT2 receptors; the precise mechanism by which this produces antiseizure effects in Dravet syndrome and Lennox-Gastaut syndrome is unknown, though 5-HT2B receptor agonism is associated with valvular heart disease and pulmonary arterial hypertension risk.
Cannabidiol is a phytocannabinoid antiepileptic; its precise mechanisms of anticonvulsant action in humans are unknown and do not appear to involve interaction with cannabinoid receptors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fintepla
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (11/12) · Qty limit (9/12)
Epidiolex
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (0/12)
UnitedHealthcare
Fintepla
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Epidiolex
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Fintepla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Epidiolex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25
ONWARD Copay Assistance Program: FinteplaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Epilepsy (Seizures): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FinteplaView full Fintepla profile
EpidiolexView full Epidiolex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.